Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Phase I/II, Residual Edema Evaluation With 0.5mg and 2.0mg Ranibizumab Formulations (REEF)

NCT01292798 is registered in ClinicalTrials.gov with California Retina Consultants as lead sponsor.

NCT NCT01292798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01292798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Phase I/II, Residual Edema Evaluation With 0.5mg and 2.0mg Ranibizumab Formulations (REEF)
Lead sponsor
California Retina Consultants
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2011
Completion date
April 30, 2013
Enrollment
43 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema